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ABSTRACT 
 
Replacement of local bone loss is a significant clinical challenge. Tissue engineering- 
based bone grafting has emerged as a viable alternative to biological and synthetic grafts. The 
purpose of this study was to evaluated an effect of enamel matrix derivative ( Emdogain ® ) on 
bioactive glass in enhancing bone formation in rat calvarium defects. Material and methods; 
Twenty rats were used in this study. In all animals, two standardized critical- size calvarial 
defects (CSD) was created surgically. The animals were randomly allocated into 4 groups of 5 
animals each. Group AI: One calvarial defect was filled with bioactive glass plus enamel matrix 
derivative (EMD), while the contralateral defect was bioactive glass alone. The healing period 
was 2 weeks. Group AII and AIII: The animals were treated in the same manner as in Group AI 
but with a healing period of 4 weeks and 8 weeks, respectively. And Group B: One calvarial 
defect was filled with enamel matrix derivative (EMD), while the contralateral defect was empty 
as control. The healing period was 8 weeks. Formation of new bone was evaluated 
radiomorphometry and  histomorphometrically. Results; No defect completely regenerated with 
bone. Bioactive glass particles were observed of both sides in groups AI, AII and AIII. The 
radiomorphometry, in group AI and AII bioactive glass with EMD had more mean optical density 
than bioactive glass alone but in group AIII, mean optical density was nearly the same. The 
histological analysis revealed that bioactive glass with EMD in group AI, AII and AIII presence 
more percentage of new bone formation than bioactive glass alone. At 8 weeks, bioactive glass 
with EMD had highest percentage of new bone formation, EMD alone, CSD and bioactive glass 
alone, respectively.   
 
 
 v
Conclusion; Bioactive glass with enamel matrix derivative had more new bone 
formation in the rat calvarial bone defects when compare with Bioactive glass alone at 2, 4 and 8 
weeks. Enamel metrix derivative alone used in the rat calvarial bone defects also had more new 
bone formation compared with unused defects. Due to the small number of rats in this study, to 
confirm the result, further study needs to be preformed. 
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CHAPTER 1 
 
  INTRODUCTION 
 
Replacement of local bone loss is a significant clinical challenge. There are a variety of 
techniques available to the surgeon to manage this problem, each with its own advantages and 
disadvantages. Several treatment procedures including bone grafts, guided tissue regeneration, 
combined approaches, and growth factors have been suggested for regenerative bone defect.  
The treatment of bony defects with various grafting materials has provided a baseline for 
what can be achieved in reference to regenerative efforts to create bone fill. While the use of 
autograft material is the preferred technique, Autogenous cancellous bone grafts produce the 
most successful and predictable results.1 Free bone grafts act mostly as scaffolds and are thus 
more osteoconductive than osteoinductive even though osteogenic activity may have remained in 
the spongious part of the graft.2 The major disadvantage of autogenous grafts is the need for a 
second surgical site and the morbidity resulting from harvesting. Allogeneic bone is non-vital 
osseous tissue taken from one individual and transferred to another individual of the same species. 
There are three forms of allogeneic bone: fresh frozen, freeze-dried and demineralized bone 
matrix (DBM). Allograft has disadvancetage of eliciting an immunological response due to 
genetic differences and the risk of inducing transmissible diseases.3 Xenogeneic bone grafts 
consist of skeletal tissue that is harvested from one species and transferred to the recipient site of 
another species.4, 5 These grafts can be derived from mammalian bones and coral exoskeletons. 
Bovine derived bone has been commonly used,6, 7 even though other sources are such as porcine 
or murine bone are available. Xenogeneic bone was popular in the 1960's but fell into disfavour 
due to reports of patients developing autoimmune diseases following bovine bone transplants.2, 8 
The re-introduction of these products in the 1990's comes after the development of methods to 
deproteinate bone particles.9 This processing reduces the antigenicity making these implants more 
tolerable to host tissues.10 Their disadvantage is the concern with the possibility of future bovine 
spongiform encephalopathy due to potential slow virus transmission in bovine-derived products.11, 
12 Since other alternative biomaterials exist, bovine derived products should probably be avoided 
until the concerns regarding potential slow virus transmission are clearly addressed. 
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Bone grafting procedures are undergoing a major shift from autologous, allogeneic and 
xenogeneic bone grafts to synthetic bone graft substitutes. Such synthetic materials could also 
play a very important role in tissue engineering,13 serving as bioactive scaffolds. Bioactive 
glasses are  groups of synthetic silica-based bioactive materials with bone bonding properties first 
discovered by Larry Hench in early 1970s. Bioactive glass has the property to promote adsorption 
and concentration of proteins utilized by osteoblasts to form a mineralized extracellular matrix 
and thus, promote osteogenesis by allowing rapid formation of bone. The material’s ability is to 
act like a hemostatic agent and to maintain the blood clot in the defect. There are references in the 
literature stating the positive properties and effects of bioactive glass as allowing the formation of 
bone–tissue bond.14 Bioactive glasses are hard, solid (non-porous) and can be regarded as a three-
dimensional silica (SiO2) network. Silicon dioxide (also known as silicate) forms the main 
component. By varying the proportions of sodium and calcium salts, phosphates, and silicon 
dioxide, forms can be produced that are soluble in vivo (solubility being proportional to the 
sodium oxide content) right through to those that are essentially nonresorbable.15 Bioactive 
glasses have different bioactivity and resorption rates depending on their chemical compositions. 
The critical feature for the rate of bioactivity is a SiO2 content less than 60% in weight. Bioactive 
glasses possess both osteointegrative,  osteoconductive properties and osteostimulatory 
capacity.16, 17  
The basis of the bonding property of bioactive glasses in their chemical reactivity in 
body (tissue) fluids, a series of chemical reactions occurs, which results in the formation of a 
hydroxyapatite layer to which bone can bond. Three general processes are leaching, dissolution 
and precipitation. The leaching reaction occurs via ion exchange mechanism. Sodium is leached 
from the glass and is replaced with protons from the solution. An important aspect of this reaction 
is that the local pH is driven from an acidic value to a neutral or slightly basic pH, which can be 
more supportive of healing. Concurrent with the leaching reaction, dissolution of the glass silica 
network occurs as hydroxyl groups attack the silicon-oxygen bonds (Si-O-Si), releasing silicic 
acid and other elements (Ca, Na, P). As silicic acid is released into solution, silanol groups from a 
hydrated layer at the glass surface. The silanol (Si-OH) groups undergo a rearrangement via a 
polycondensation reaction to produce a silica gel. The silica-rich gel has a large surface area and 
a negative surface charge. This leaves behind a silica-rich gel approximately 200 µm thick. This 
gel serves as a nucleation site for the formation of a calcium phosphate (CaP) layer. The CaP 
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phase that accumulates at the surface of the silica gel is initially amorphous, but subsequently 
crystallizes to a hydroxycarbonate apatite structure by incorporating carbonate anions from the 
solution within the amorphous CaP phase. Organic species in the local environment such as 
collagen, chondroitin sulfate, and glycosaminoglycans, are incorporated into this bioactively 
forming layer. Osteoblasts are attracted to the hydroxycarbonate apatite and release organic 
constituents, followed by mineralization.(Figure 1.) The end result is a bonded interface 
consisting of a series of layers: glass - silica gel - hydroxycarbonate apatite - bone. A 
mechanically strong bond between bioactive glass and bone forms as a result of a silica-rich gel 
layer that forms on the surface of the bioactive glass when exposed to physiologic aqueous 
solutions. Within this gel Ca2+ and PO42– ions combine to form crystals of hydroxyapatite (HA) 
similar to that of bone.3, 18 It has been reported that leaching reaction of bioactive glass particles 
in vivo results in the formation of niches in which bone can form.19 This bone is apparently 
unconnected to the surrounding bone (Figure 2.), and these islands of bone may form nuclei for 
the formation of additional bone, which may eventually become confluent with the surrounding 
native bone. When used as a preformed implant they have significantly greater mechanical 
strength when compared to calcium phosphate preparations such as ceramic HA.15 They have 
several unique properties compared with other synthetic bioresorbable bioactive ceramics, such 
as calcium phosphates, hydroxyapatite and tricalcium phosphate (TCP).  
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Figure 1.   Sequence of interfacial reactions involved in forming a bond.20 
 
 
 
 
Figure 2.   Micrograph of bioactive glass particles (BG). The core of the granule has been       
                  excavated, and new bone tissue deposition on the outer and inner surface can be  
                  observed (NB) (hematoxylin-eosin stain, original magnification x 200).21 
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Factors affecting dissolution of bioactive glass to be used as tissue engineering scaffolds 
The solution parameters of initial pH, ionic concentration and temperature have a large 
effect on the rate of scaffold dissolution and even type of calcium phosphate precipitated. Ionic 
concentration and therefore pH, will obviously change with time as dissolution progresses and 
this will in turn affect the dissolution rate. If pH rises above a critical value, cytotoxicity will 
occur. 
Three types of media have been used during bioactive glass dissolution experiments: 
i) Tris-buffer, a simple organic buffer solution. 
ii) Simulated body fluid (SBF), a tris buffer containing similar ion concentrations to that of 
human blood plasma. 
iii) Alpha-MEM and D-MEM, culture media that contain both the inorganic and biological 
organic components of blood plasma. 
Bioactive glass underwent a faster surface reaction and exhibited a larger 
hydroxycarbonate apatite (HCA) crystal size in Tris solution than it did in SBF or culture 
medium. However, Pereira et al. found that  HCA nucleated faster in SBF than in Tris, which are 
put down to the far higher initial phosphorus concentration (40 ppm) in SBF, thus aiding HCA 
nucleation.22 A similar result was found by Tsura et al.,but they suggested that the dissolution of 
Ca2+ ions from materials would increase the degree of supersaturation in the solution(SBF), 
which would already be supersaturated regarding HCA precipitation and hence make it much 
easier for HCA to be precipitated.23  
Increasing the pH or Ca2+ concentration of SBF containing porous silica gel-glass 
reduced the induction time for hetetogeneous HCA formation. Reaction kinetics of surface layer 
formation have been found to alter in culture media containing serum. This dues to the adsorption 
of serum proteins onto the surface of the bioactive glass forming a barrier to nucleation of the 
HCA layer.24 
Several in vitro studies have shown the nontoxicity of bioactive glass, its positive 
influence on osteoblast culture in term of studies suggest a direct and very positive effect of 
soluble silicon on mineralization, inhibitory capacity on fibroblast proliferation and ability to 
form calcification foci in periodontal ligament fibroblasts. The cellular activity of bone growing 
cells is enhanced on a bioactive glass surface25, and the attachment and spreading time of certain 
fibroblasts are slowed down on the bioactive glass surface compared with an inert surface.26 
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Histologic studies in animals have shown that bioactive glass implanted in non-
periodontal sites is biocompatible and incorporates into the bone tissue thus producing an alkaline 
pH at the implantation site.16 Animal studies using the primate model demonstrate bone 
apposition in direct contact to particles of bioactive glass. The effect of bioactive glass on cellular 
activity observed in tissue culture studies may contribute to the inhibition of epithelial 
downgrowth noted in the repair of bony defects in a primate model. 26, 27 The mechanism of this 
phenomenon  may be related to rapid collagen attachment to the silica-gel surface of the reactive 
bioactive glass particle. The rapidly formed connective-tissue seal may serve to block epithelial 
downgrowth. In vivo, the material is highly osteoconductive and it seems to promote the growth 
of new bone on its surface. The bioactive glass was mostly resorbed and replaced by bone and the 
remaining granules were in close contact with bone.28 There is a dynamic balance between 
intramedullary bone formation and bioactive glass resorption. The effect of bioactive glass 
particle in medullary bone around titanium implant, show increase in reactive medullary bone 
formation.29 
In an animal model, the speed of bone growth around bioactive glass particles was much 
faster than bone formed around hydroxyapatite particles.30 In addition, the bone formed around 
bioactive glass was much denser and more mature compared with bone formed around 
hydroxyapatite particles. When compared with autologus bone in the augmentation of surgically 
created defects in the canine rib model,  bioactive glass led to more bone than autologous bone 
alone, and 50/50 mixtures of bioactive glass and autologous bone led to twice as much bone 
formation in the 6-week experiment than autologous bone alone. 
Recent studies of molecular biology have shown that bioactive glass induces a high local 
turnover of bone formation and resorption. Many osteoporotic fracture patients are candidates for 
concurrent treatment with bisphosphonates and bioceramic bone graft substitutes. Since 
osteopromotive silica-based bioactive glasses induce accelerated local bone turnover, adjunct 
antiresorptive agents may affect the process. However, a recent study showed that an adjunct 
antiresorptive therapy (zoledronic acid) is even beneficial for bone incorporation of bioactive 
glass. And have study that shown the activity of the bioactive glass material was found even to 
overshadow the effect of BMP-2 gene therapy. Based on these observations, bioactive glasses are 
a promising group of unique biomaterials to act as bone graft substitutes.31 
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Biograns (Orthovita, Implant Innovations, Palm Beach Gardens, FL, USA) is a 
resorbable amorphous bioactive glass supplied in granules that are approximately 300–355 µm in 
diameter. They consist of 45% SiO2, 24.5% CaO, 24.5% Na2O and 6% P2O5.  It is conceivable 
that this material appears to resorb by dissolution rather than by osteoclastic activity. 
Bone regeneration techniques increasingly rely on the use of exogenous molecules able 
to enhance tissue formation in pathologic and traumatic defect. Bioactive glass may be an 
attractive vehicle for delivering osteogenic agents to regenerative sites. Enamel matrix 
derivatives (EMD) are harvested from around developing teeth in carefully selected young pigs 
and, following special processing procedures. They are the major component of commercially 
available Emdogain® (Biora AB, Malmö, Sweden). (Figure 3.) 
 
 
 
 
                    Figure 3.   Emdogain® (Biora AB, Malmö, Sweden). 
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Most of the initial work with this material has been aimed at regenerating periodontal 
attachment apparatus lost due to periodontitis, but other applications are being explored. The 
main biological effects of EMD have been attributed to their predominant protein, amelogenin, 
with the remaining fraction comprising less-characterized factors. Amelogenin is not a classic 
growth factor, but rather a cell-adhesion matrix-bound protein. Specific amelogenin gene 
products are thought to have activity as epithelial–mesenchymal signaling molecules. In addition, 
there is evidence that the alternate splice variant of the amelogenin gene, leucine-rich amelogenin 
peptide may also have direct signaling activities on cementoblasts, and, thus at least by 
implication, osteoblasts.32 
The enamel matrix derivative was generally believed to regulate the initiation, 
propagation, termination and maturation of the enamel hydroxyapatite crystallites. Other findings 
indicate that the enamel matrix also has a function outside the developing enamel. Enamel matrix 
proteins are temporarily deposited onto the dentinal root surface and provide an initial and 
essential step in the formation of acellular cementum. Autoradiographic and scanning electron 
microscopy studies provide additional evidence that, following apoptosis of hertwig epithelial 
root sheath (HERS) cells and deposition of the enamel matrix proteins onto the dentin surface, 
the cementogenesis process is initiated and kept modulated by these proteins. Subsequently, 
when cementum has been laid down onto the enamel-matrix-covered dentin surface, an 
attachment apparatus will develop. Immunological and immunohistochemical methods both show 
that enamel matrix proteins are present in acellular cementum, accentuating the importance of 
these proteins in the cementogenesis process.33 
Enamel matrix derivative has been used clinically for periodontal regeneration, and its 
therapeutic effectiveness has been variously attributed to amelogenin, nonamelogenin enamel 
matrix proteins and  growth factors.  While EMD may induce periodontal regeneration, the 
precise mechanism of this is not known.34 Enamel matrix proteins have been suggested to exert 
its influence locally by stimulating cellular activation in cell culture that resembles process 
critical for healing. Enamel matrix derivative effects on cells depend on their phenotype and 
differentiation stage. In vitro studies show that EMD can increase matrix production, 
proliferation and bone nodule formation of periodontal ligament cell cultures and the 
proliferation and differentiation of human and murine osteoblast cell lines, with the stimulation of  
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phenotypic bone markers in some osteoblast cell lines.35-38 Narukawa M et al. studied that EMD 
stimulates osteoblastic differentiation via the induction of mRNA of osteogenesis-related 
transcription factors. And the study in vitro of Galli C et al., found significantly higher quantity 
of OPG and lower amount of RANKL and alkaline phosphatase activity and osteocalcin 
production were enhanced in cultures. Mineralized nodules appeared bigger and more numerous 
in cultures.38 EMD stimulates not only the transcription level but also the maturation stage.39 In 
contrast, some studies show no effect of EMD on osteoblastic differentiation, although other 
growth factors were stimulated.32, 40   
The search for downstream target genes has also revealed EMD response elements in the 
rat bone sialoprotein gene promoter that may mediate the effects of EMD on bone sialoprotein 
gene transcription. Bone sialoprotein is a unique marker of early osteogenic differentiation that 
can regulate the formation of mineral crystals. Amelogenin increases expression of bone 
sialoprotein gene through a tyrosine kinase pathway.41 A cDNA microarray study examining 
EMD-mediated changes in gene expression in periodontal ligament cells in vitro has reported the 
downregulation of genes involved in the early inflammatory phases of wound healing, while 
simultaneously upregulating genes encoding growth and repair-promoting molecules. The in vitro 
treatment of cementoblasts with EMD was found to decrease osteocalcin expression and to 
increase osteopontin expression. In 2006 Reseland JE et al. found that EMD had a positive effect 
on factors involved in mineralization in vitro, causing an increased alkaline phosphatase (ALP) 
activity in the medium as well as increased expression of osteocalcin and collagen type I. Several 
hundred genes are regulated by EMD in primary human osteoblasts. There appear to be 
similarities between the effects of EMD and parathyroid hormone (PTH) on human osteoblasts. 
Some study about expression pattern of several mRNAs and proteins upon EMD stimulation also 
indicates a secondary osteoclast stimulatory effect, suggesting that the osteogenic effect of 
EMD.35 And it has been reported that EMD can induce osteoclast formation through RANK-
RANKL interactions in mouse marrow cultures.42, 43 It indicate that EMD plays an important role 
in the production of RANKL in osteoblasts during the process of osteoclastogenesis, suggesting 
that it may participate in bone regeneration through bone formation and bone resorption.43 
Narukawa M et al. in 2007 found EMD induced osteocalcin and type II collagen mRNA in 
undifferentiated mesenchymal cells.39 Hattar S et al.(2005) finding bioactive granules coated with 
Emdogain revealed significantly higher protein production than the bioactive granules alone. 
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That have the ability to support the growth of osteoblast-like cells in vitro and to promote 
osteoblast differentiation by stimulating the expression of major phenotypic markers.44 
Overall, the data support the positive effect of EMD on osteoblast differentiation, 
although further studies are needed to clarify which molecules in EMD stimulate osteogenesis 
and to define their precise modes of action.32  
 
COMPOSITION OF THE ENAMEL MATRIX PROTEINS 
The major fraction of the enamel matrix proteins is composed of three matrix proteins, 
corresponding to amelogenin, enamelin, and sheathlin (also called ameloblastin or amelin). The 
amelogenin, a family of hydrophobic proteins and insoluble in water at neutral pH, is account for 
more than 90% of the organic constituent of the enamel matrix. The amelogenin has remained 
remarkably well-conserved through evolution, suggesting that it may have great functional 
importance. The second largest component of the enamel matrix proteins is the enamelin, it also 
contains several proteinases. Since the enamelin was found to contain serum proteins, the more 
general term "nonamelogenin" is now commonly used to describe this high-molecular-weight 
fraction. It includes proline-rich enamelin, tuftelin, and tuft proteins. Two enzymes, 
corresponding to human matrix metalloproteinase 20 (MMP-20)  and Enamel matrix serine 
proteinase 1 (EMSP1), have been purified and the cDNA cloned from developing porcine teeth. 
These proteins are all present in EMD. Although early immunoassay studies could not identify 
the presence of growth factors in EMD, nominal levels of transforming growth factor β1 (TGF-
β1) have been detected immunologically. In addition, by using the bone morphogenetic protein 
(BMP) binding protein noggin, investigators have identified BMP-2 and BMP-4 like in an 
osteoinductive fraction of enamel extracts.33, 45 The presence of BMP-6-like molecules in EMD 
were determined later.39 The osteogenic activity of EMD may be mediated by the induction of 
BMP-like molecules, as EMD induce Cbfa1, Runx2, Sox9 expression and the phosphorylation of  
mothers against decapentaplegic homolog 1 (Smad1), both of which can be blocked by the BMP 
inhibitor, noggin.32, 39 
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EMDOGAIN® FORMULATION33 
A commercial enamel matrix derivative (Emdogain®, Biora AB, Malmö, Sweden) 
received FDA approval and is now available for the treatment of periodontal defects. It is a 
purified acidic extract of developing embryonal enamel derived from six month-old piglets. Its 
purpose is to act as a tissue-healing modulator that would mimic the events that occur during root 
development and to help stimulate periodontal regeneration. (Figure 4.) 
 
 
 
     Figure 4.  Cells that have effected from enamel matrix derivative in periodontal lesion 
 
In Vivo studies 
Factors influencing healing of the defect in animal models. 
1 . age    Immature animal can more actively repair an osseous defect than an older one; 
therefore, a true test for a bone repair material should involve an adult animal.46 
2. wound size   An experimental bony wound used to assess repair should, therefore, be large 
enough to preclude spontaneous healing. An experimental bony wound of this nature may be 
termed a critical size defect (CSD). The CSD may be defined as the smallest size intraosseous 
wound in a particular bone and species of animal that will not heal spontaneously during the 
lifetime of the animal.46 
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Histological evaluation of the effects of enamel matrix protein derivative on bone 
formation, it has been demonstrated that EMD possesses an osteo-promotive effect on bone and 
medullary regeneration during wound healing of injured long bones.47 EMD is also an effective 
biological matrix for enhancing new trabecular bone formation in rat femer48and skull.49 However 
EMD when used alone in the defect site, dose not significantly promote bone healing in rabbit 
modal.50-52 The effects of enamel matrix protein derivative next to implant contact in the dog 
model have positively on bone healing after guided bone regeneration52same as the study Boyan 
BD (2000) that studied in calf muscle of nude miced, enamel matrix derivative mixed with  active 
demineralized freeze dried bone allograft induce new bone formation. But when combination 
EMD with inactive demineralized freeze dried bone allograft or used alone did not induce new 
bone that indicate EMD is not osteoinductive but it is osteopromotive , due in part to its 
osteoconductive properties.37, 53 Donos N.(2005) he found enamel matrix derivative mixed with 
deproteinized bovine bone mineral ( xenografts ) and graft at lateral aspect of mandibular ramus 
did not positively affect the amount of new bone formation.54 And in 2006 he used  deproteinized 
bovine bone mineral mixed with enamel matrix derivative implant in pectoralis muscle of rat not 
have bone-inductive properties.53 Murai in 2005 studied the effects of the enamel matrix 
derivative and β-tricalcium phosphate on bone augmentation in calvarium of rabbit, found the 
mixture of enamel matrix derivative and  β-tricalcium phosphate not have significant to increase 
in the amount of new tissue and mineralized bone but tend to increase the new bone55 at least 
partly, involves stimulation of bone remodeling.35  
 
In the Clinical studies  
Emdogain® has been tested as a new chemical entity with a safety program 
encompassing single- and multiple dose studies (intravenous and subcutaneous), local irritation 
tests (subcutaneous and topical), and  in vitro tests for cell toxicity and mutagenicity. No adverse 
results were found. Enamel matrix proteins are expected to be recognized as “ self ” by the 
human immune system, because everyone is exposed to them during tooth development in early 
childhood. The protein in Emdogain® is of procine origin with very high homogeneity to the 
human amelogenins. Emdogain® is purified through a number of processing steps, including 
solvent and heat treatment, ultrafiltration, sterile filtration and freeze drying.  
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In the physiologic environment of the periodontal lesion with neutral pH and body 
temperature, the viscous vehicle solution become watery and rapidly leaves the application site, 
while the protein change to its natural. 
Ten occupationally exposed employees from the laboratories where Emdogain was 
developed and procedued were tested for type IV sensitization by using skin tests result to 
negative(buffer) and positive (histamine) controls. No reaction was seen either immediately or 
within the 48 hours following testing. One year later the same employees volunteered for a 
challenge injection of Emdogain® protein and blood sample were taken before and a month after 
this injection. The result was again unchanged; no immunoresponse was elicited.56 
All clinical studies with Emdogain® have included active questioning of patients for 
subjective adverse reactions and have required dentists to note any objective reactions. 
Comparisons in clinical studies between the test surgeries with Emdogain® and identical control 
surgeries without Emdogain® show no differences in type or frequency of common procedure-
related experiences such as root sensitivity, mucosal irritation and so on. When certain antibiotics 
were used, well-known side effects (eg. Skin reactions and gastrointestinal problems) were 
detected.56, 57  
Karl J. Zeren in 2006 had reported a surgical technique that preserves anterior esthetics 
by immediate implant placement. This approach capitalizes on the potential for freeze dried bone 
allograft (FDBA) and EMD to assist in bridging the osteogenic “ jumping distance” to achieve 
ridge preservation and bone augmentation. The composite graft material is considered for 
predictably resolving osseous voids and promoting implant integration.58 
                 
Objective  :  
The aim of this study is to evaluate an effect of enamel matrix derivative (Emdogain®) 
on bioactive glass in enhancing bone formation in rat calvarium defects. 
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CHAPTER 2 
 
MATERIALS & METHODS  
 
This study has been approved by the animal experiment ethical committee of Prince of 
Songkla University.    
 
Animals   
Twenty, male, 5-month old, albino rats of the Wistar strain were used in the study.The 
animals were fed rat chow and water, and kept separately in cages at the animal house  24ºC and 
55% relative humidity in at least 12 hours light per day.  
 
Anaesthesia and surgery 
The animals were given atropine 0.05 mg/kg before anaesthetized with intramuscular 
injection of Tiletamine and Zolazepam 20 mg/Kg about 5 minutes prior to surgery. Hair over the 
calvarium was shaved and  disinfected with betadine solution. The animal was then draped to 
allow aseptic access in the operation field.  
 
 
 
 
 
Figure 5.  The rat was injected with Tiletamine and Zolazepam before  the operation. 
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A midline incision was cut through the skin of the calvaria, and then the cranial skin flap 
was elevated. The subcutaneous fascia was divided, periosteal flaps were reflected bilaterally and 
the cranial vertex was exposed.  
 
 
 
 
 
 
 
Figure 6.  The rat was disinfected with betadine solution and draped.  
Figure 7.  A midline incision was through the skin of the calvaria. 
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Figure 8.  A cranial skin flap was elevated.  
Figure 9.  The subcutaneous fascia was divided and periosteal flaps were reflected  
                 bilaterally. 
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Two bone defects were created in the left and right parietal bone using trephine bur (5.0 
mm. diameter) in slow-speed micromotor under copious saline irrigation with depth equal to the 
full thickness of the calvarial bone. The 2 pieces of calvarial bone were removed carefully to 
avoid injury to the dura mater.  
 
 
 
Reference markers were made with round bur 2 mm. anterior and 2 mm. posterior  to the 
margin of each defect, both of which were located on a saggital axis bisecting the surgical defect. 
Gutta-percha was filled in the marker holes as radiographic landmarks.   
 
 
 
 
Figure 11.  Reference markers were made 2 mm. anterior and 2 mm. posterior  to 
                  the margin of defects. 
Figure 10.  Two bone defects were created in the left and right parietal bone. 
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The rats were randomly allocated into group A and group B, 15 rats and 5 rats 
respectively. In group A, bioactive glass 0.04 g mixed with EMD 0.01 cc.(Emdogain® Gel, Biora 
AB, MalmÖ, Sweden) by spatula was filled randomly in one side of the defect and the 
contralateral side was filled with bioactive glass 0.04 g alone. Healing period in group A was 
devided into 3 subgroups (2 weeks,  4 weeks and 8 weeks), 5 rats per subgroup. In group B EMD 
0.01 cc. was randomly filled in one side of the defect, the contralateral side was empty. The 
healing period of group B is 8 weeks. 
 
 
 
 
 
 
 
Figure 12.  Biograns® (Bioactive glass) And Emdogain® (Enamel matrix derivative). 
Figure 13.  Bioactive glass mixed with the enamel matrix derivative on the right side 
                   and bioactive glass alone on the left side.  
  
19
Soft tissue and skin were closed with 4-0 Vicryl® resorbable sutures (Ethicon). At the 
end of the surgical procedures, all animals were received a single intramuscular injection of 
antibiotic (Ampicillin, 100 mg/Kg). All animals were fed with standard diet and water filled with 
Ibuprofen, 20-40 mg per Kg. three day post-operation and pure water until the date of sacrifice.  
 
 
 
 
 
 
 
 
 
 
Figure 15.  After operation the wound was applied with betadine solution. 
Figure 14.  The flap was closed layer by layer.  
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Qualitative Evaluation 
The rats were sacrificed by overdose intraperitoneal injection of Pentobabitone 
(Nembutal®) and calvarial bones were resected, including a 3 mm. margin of normal bone 
around the surgically treated area. Sample of the soft tissue and periosteum were also collected. 
The specimens were visually examined for the signs of inflammation. Osteogenesis was assessed 
both radiologically and histomorphologically.   
 
 
 
 
 
 
 
 
 Figure 17.  The specimen from rat cranium (dura site). 
Figure 16.  The specimen from rat cranium (Periosteum site). 
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Quantitative Radiodensitometry 
Radiographs of all specimens were taken using Gendex X-ray machine with 75 kvp, 10 
mA, 0.26 sec and the Super Polysoft Insight Kodak X-ray film (Kodak Ultra-speed , Eastman 
Kodak company, Rochester, NY). The distance between the film and focal spot were kept on 50 
cm in every subject. An aluminum 5 steps wedge was used for film calibration. The films were 
automatically processed using by Dent-X9000 processor. The radiographs were scanned using 
Bio-Rad® Model GS-700 Imaging Densitometer (BIO-RAD Laboratories Ltd, Hemel Hempstead, 
UK) to obtain digital radiographic images of the specimens and analysed with Molecular 
Analyst® software. The average radiographic optical density (Mean OD) was measured and 
calculated for comparing the amount of mineralized tissue produced in response to each type of 
graft material. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18.  Radiograph was taken with parallel technique. 
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Figure 19.  Bone specimen and aluminum steps wedge were attached to the periapical 
                   film. 
Figure 20.  Imaging Densitometer Unit. 
  
23
Histologic preparation 
All specimens were fixed with 10% buffered formalin solution and decalcified with 10% 
formic acid. After completion of decalcification, each bone specimen was divided into 4 pieces as 
shown in figure 21. 
                                     1              2                3               4 
 
 
 
 
  
 
 
 
All bone specimens were embedded in paraffin and serially cut in 5 µm thick. Each 
histologic section was stained with haematoxylin and eosin (H&E) stain. These slides were 
studied blind under light microscope for detection of new bone formation, soft tissue reaction and 
the degree of inflammation. 
Histomorphometric evaluation 
Computer-assisted histomorphometry was performed in order to measure the amount of 
newly formed bone in the defect. To obtain digital histologic images, a digital camera 
(AxionCam MR , Carl Zeiss , light microscopy , Gottingen , Germany) was attached to light 
microscope and using Axiovision program. Measurements was carried out directly at the 
magnification of 5×, by the light microscope. These histologic images were transferred to a 
computer and measured region of bony defect area and new bone formation in the experimental 
and control site, using Image-Pro Plus 5.0 program The percentage of new bone area in the 
experimental and control bone defect were estimated ;   
                    
                         
 
 
Figure 21.  The specimen was divided to make histologic.  
      % new bone    =    new bone area  × 100 
                                Total bone defect area 
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Data analysis  : The analyses were performed by using commercial SPSS software (version 14.0, 
Standard Software Package Inc., USA). Calculations of mean numbers for each specimen,  follow 
by computation of group mean number and standard deviation, were carried out in all 
measurements.  
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CHAPTER 3 
 
RESULTS 
 
Clinical observation 
After the animals were grafted in the calvarial bone defects. Three rats were excluded 
from the study due to postoperative complication and wound infection. Two excluded rats were 
from group AI (Bioactive glass + EMD vs. Bioactive glass alone, healing period 2 weeks) and 
one from group AII (Bioactive glass + EMD vs. Bioactive glass alone, healing period 4 weeks). 
All other animals remained healthy during the observation period and all implantation sides 
healed uneventfully. After full recovery, they were able to eat the pellet food and drink water. 
 
Gross Examination 
After sacrifice, the specimens were examined and found that 3 samples from the group 
AIII (Bioactive glass + EMD vs. Bioactive glass alone, healing period 8 weeks) and 2 samples 
from the group B (Enamel matrix derivative alone vs. Empty) had inflammation. Other samples 
revealed the graft appeared well incorporated in experimental and control side in group A 
(Bioactive glass + EMD vs. Bioactive glass alone). But in group AIII were better than group AII 
and group AI, respectively. In group AI, the graft had been showed the same incorporated in 
experimental and control side, but less than group AII. The consolidation of Biograns® particle 
was showed as same as between the experimental and control side in each specimen, but in group 
AIII the Biograns® particle was shown more consolidation than group AII and the latter was 
shown more consolidation than group AI.  
 
In group AI (Bioactive glass + EMD vs. Bioactive glass alone, healing period 2 weeks), 
Bioactive glass particles were observed in both side of bone defect in all specimens and showed 
well incorporated with sounding bone. The defects area had flat surface and bone defect margins 
of both side could be observed. (Figure 22) 
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In group AII (Bioactive glass + EMD vs. Bioactive glass alone, healing period 4 weeks), 
Bioactive glass presented homogenously in the whole area of bone defects with hard consistency. 
The defect area had flat surface and bone defect margins of both side still be observed. (Figure 
23.) 
In group AIII (Bioactive glass + EMD vs. Bioactive glass alone, healing period 8 weeks), 
Bioactive glass was filled with dense bone-like tissue in all specimens. The defect area had flat 
surface. The dense bone-like tissue also extended over the edge of bone defects. (Figure 24.) 
In group B (Enamel matrix derivative alone vs. Empty, healing period 8 weeks),  
Specimens were occupied by soft fibrous tissue in all of 3 specimens. The surface of the defect 
area was flat and soft in consistency. The dense bone-like tissue also extended over the edge of 
bone defects. (Figure 25.) 
 
The gutta-percha markers were showed a biocompatible material because there were no 
sign of infection at the markers. These markers were helpful for location the bone defect margin 
especially from the radiographs. Although, the bone defect margin of both side could be observed 
in all specimens, the bone defect margin of the specimens in group B were more obviously to 
detect than in group AI, AII and group AIII respectively.     
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Figure 22.   Specimen of rat calvarial 2 weeks after grafting with bioactive glass mixed with 
                   enamel matrix derivative and bioactive glass alone (Group AI). On the periosteal  
                   side of the rat calvarial (A). On the endocranium side of the rat calvarial (B). 
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Figure 23.   Specimen of rat calvarial 4 weeks after grafting with bioactive glass mixed with              
                    enamel matrix derivative and bioactive glass alone (Group AII). On the periosteal  
                    side of the rat calvarial (A). On the endocranium side of the rat calvarial (B). 
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Figure 24.   Specimen of rat calvarial 8 weeks after grafting with bioactive glass mixed with 
                    enamel matrix derivative and bioactive glass alone (Group AIII). On the periosteal  
                    side of the rat calvarial (A). On the endocranium side of the rat calvarial (B). 
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Figure 25.   Specimen of rat calvarial 8 weeks after grafting with enamel matrix derivative  
                   alone and empty defect (Group B). On the periosteal side of the rat calvarial (A).  
                   On the endocranium side of the rat calvarial (B).  
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Radiographic Evaluation  
In the period of 2, 4 and 8 weeks, from radiographic evaluation, well-delineated round 
bone defects were observed together with the radiopaque areas of bone graft materials in situ. 
(Figure 26, 27) The gutta-percha markers could also be observed in all specimens. The 
radiodensity of all the defects, experimental and control sides, seemed to appear the same as 
shown in Table 1.  
 
 
 
 
Figure 26.   Radiograph of group A grafted with bioactive glass plus enamel matrix derivative  
                and bioactive glass alone. The defect margins were observed, experimental side  
                (right) was shown a radiopacity as well as the control side (left). 
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Figure 27.   Radiograph of group B grafted with enamel matrix derivative alone and control  
                   side(empty cavity) healing period 8 weeks. The defect margin were observed,  
                   experimental side (left) was shown a radiopacity as well as the control side  
                   (right). 
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Radiomorphometric analysis 
The values, established to characterize the amount of mineralized tissue produced in 
response to all type of graft material, were represented as the average radiographic optical density 
(Mean OD). Each defect side was measured for Mean OD value and calculated for the average 
and standard deviation as listed in Table 1.  
 
Table 1.  The data of radiomorphomeric optical density in group A and B 
n = 5 
Group Week Mean optical density 
(Mean± SD) 
 
AI 
AII 
AIII 
B 
 
 
2 
4 
8 
8 
 
Experiment Control 
           0.607 ± 0.031 
           0.627 ± 0.035 
           0.677 ± 0.087 
           0.626 ± 0.015 
 
           0.597 ± 0.015 
           0.601 ± 0.050 
           0.678 ± 0.063 
           0.641 ± 0.007 
 
 
Group A    Experimental side = Bioactive glass + Enamel matrix derivative 
                  Control side = Bioactive glass only 
Group B    Experimental side = Enamel matrix derivative only 
                  Control side = Empty 
 
The data was shown that the radiodensity in the experimental side was slightly more 
radiolucent than the control side in group A 2 and 4 weeks. But in group AIII and B the 
radiodensity in the control side was slightly more radiolucent than the experimental side. 
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Figure 28.  Distribution of mean optical density in rat’s calvarial specimens. 
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Histological Evaluation  
Microscopically, there was only minimal bone growth in the defect area with no bridging 
of the defect in all studied. Group AI Specimen of rat calvarial 2 weeks after grafting with 
bioactive glass mixed enamel matrix derivative (Figure 29, 30) and bioactive glass alone (Figure 
31, 32). The bone edge of the defect presented an irregular morphological appearance, with small 
areas of reparative bone neoformation in both the groups except only one specimen in the control 
side. A large number of residual of bioactive glass particles were observed with osteoprogenitor 
cells permeating the intergranular spaces. Fibrous connective tissue was found in the both defects.  
 
 
 
 
Figure 29.   Saggital histological section through the calvaria showing defect from the critical 
                   size bone graft with bioactive glass plus enamel matrix derivative after 2 weeks.  
                   Note the bony ingrowth from the margins defect and have new bone supradural  
                   region (Specimens stained with Hematoxylin and Eosin). Arrows indicate the 
                   margins of the defect prepared initially.  
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Figure 30.   Healing of defect group AI (2 weeks) after grafted with bioactive glass plus  
                   enamel matrix derivative (experimental side), demonstrating dense fibrous  
                   tissue around the particles and new bone deposited at the margin of the defect.  
                   (Specimens stained with Hematoxylin and Eosin, original magnification ×5)  
 
 
 
 
Figure 31.   Saggital histological section through the calvaria showing defect from the critical 
                   size bone graft with bioactive glass alone after 2 weeks. (Specimens stained with  
                   Hematoxylin and Eosin). Arrows indicate the margins of the defect prepared 
                   initially.  
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Figure 32.   Healing of defect group AI (2 weeks) after grafted with bioactive glass alone  
                   (control side), demonstrating dense fibrous tissue around the particles and newly  
                   formed bone deposited at the margin of the defect with an orientation that differs  
                          from that of the pre-existing bone. The bioactive glass particles were seen in the                      
                   defect (Specimens stained with Hematoxylin and Eosin, original magnification  
                   ×10).   
 
Group AII Specimens of rat calvarial bone 4 weeks after grafting with bioactive glass mixed 
enamel matrix derivative (Figure 33, 34) and bioactive glass alone (Figure 35, 36). The 
histological observations were similar to the 2 weeks observation. At the bone edges of the 
defects, bone neoformation with limited expansion, the new bone extended from the defect 
margin and grown into the central portion of the bone defect. In the fibrous and organized stroma 
there were vascular proliferations. The particles of the material frequently presented complete 
and incomplete penetration and there was deposition of noncollagenous amorphous material on 
them. Progressive osteoprogenitor cell invasion into these intragranular spaces were observed 
(Figure 34, 36). In experimental group, there was one specimen presented an area of 
mineralization in supradural region.  
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Figure 33.   Saggital histological section through the calvaria showing defect from the critical  
            size bone grafted with bioactive glass plus enamel matrix derivative after 4 weeks.       
            (Specimens stained with Hematoxylin and Eosin). Arrows indicate the margins of  
            the defect prepared initially.  
 
 
 
 
Figure 34.   A specimen from group AII (4 weeks) after grafted with bioactive glass plus  
                    enamel matrix derivative (experimental side), demonstrating numerous  
                    fibroblasts.The bioactive glass particles were presented fragmented appearance,  
                    presenting osteoprogenitor cell infiltration into these fissures. Deposition of  
                    dense connective tissue was also presented in these areas(Specimens stained  
                    with Hematoxylin and Eosin, original magnification ×20)  
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Figure 35.   Saggital histological section through the calvaria showing defect from the critical 
                   size bone grafted with bioactive glass alone after 4 weeks. (Specimens stained  
                   with Hematoxylin and Eosin). Arrows indicate the margins of the defect prepared 
                   initially.  
 
 
 
 
Figure 36.   A specimen from group AII (4 weeks) after grafted with bioactive glass alone  
                   (control side), Bioactive glass particle showing cracks and excavated centers  
                   with invasion of osteoprogenitor cell. Amorphous material can also be observed  
                   in some excavated centers.(Specimens stained with Hematoxylin and Eosin,  
                   original magnification, ×20)  
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Group AIII Specimen of rat calvarial 8 weeks after grafting with bioactive glass mixed enamel 
matrix derivative (Figure 37, 38) and bioactive glass alone (Figure 39, 40). At the bone edges of 
the defect, bone neoformation with expansion in direct contact with the particles of the bioactive 
glass was noted. A lower number of residual bioactive glass particles were observed within the 
bone defects and a greater amount of dense, organized connective tissue. At this time, the 
particles appeared to be more fragmented. The histologic appearance showed an increase in bone 
formation over the time, noticeable that the new bone formation found in 8 weeks was greater 
than in 4 and 2 weeks, respectively. In a few cases, there were areas of mineralization in 
supradural linear plates without any explanation. However, in experimental groups there were 
more new bone at the edge of the defects. Moreover, the histologic examination revealed the 
amount of new bone ingrowth on experimental sides was greater than the control sides. 
 
 
 
 
Figure 37.   Saggital histological section through the calvaria showing defect from the critical  
            size bone grafted with bioactive glass plus enamel matrix derivative after 8 weeks.  
            (Specimens stained with Hematoxylin and Eosin). Arrows indicate the margins of  
            the defect prepared initially.  
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Figure 38.   A specimen from group AIII (8 weeks) after grafted with bioactive glass plus  
                    enamel matrix derivative (experimental side), bioactive glass particles presented  
                    with cracked appearance and osteoprogenitor cell infiltration into these fissures.  
                    (Specimens stained with Hematoxylin and Eosin, original magnification, ×20)  
 
 
 
 
Figure 39.   Saggital histological section through the calvaria showing defect from the critical  
                   size bone grafted with bioactive glass alone after 8 weeks. (Specimens stained  
                   with Hematoxylin and Eosin). Arrows indicate the margins of the defect prepared 
                   initially.  
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Figure 40.   A specimen from group AIII (8 weeks) after grafted with bioactive glass alone  
            (control side), dense connective tissue was covering the particles. Fibrous septation  
             and deposition of noncollagenous amorphous matter were presented in the particles. 
            (Specimens stained with Hematoxylin and Eosin, original magnification, ×20)  
 
Group B Specimens of rat calvarial 8 weeks after grafting with enamel matrix derivative alone 
(Figure 41, 42, 43) and without grafting (Figure 44, 45, 46), Histologic evaluation of these 
specimens revealed a thin fibrous across the defect with small amounts of new bone being 
occasionally seen at the bony margin of the defect (Figure 43, 46). In the central areas of the 
defect, the connective tissue appeared to be thinner with a smaller number of collagen fibers. In 
two specimens, there were small new bone formations in supradural regions. All specimens were 
well vascularized and rich in fibroblasts with oriented collagen fibers.  
 
 
 
 
 
 
 
 
  
43
 
 
Figure 41.   Saggital histological section through the calvaria showing critical size defect filled  
                   with enamel matrix derivative alone after 8 weeks. Surgical defect with fibrous  
                   connective tissue was thinner than the original calvaria. Interstitial spaces were  
                   completely filled with dense connective tissue (Specimens stained with Hematoxylin  
                   and Eosin). Arrows indicate the margins of the defect prepare initially.  
 
 
 
 
Figure 42.   A specimen from group B at 8 weeks filled with enamel matrix derivative  
            (experimental side). New bone was observed at the defect edges. (Specimens  
             stained with Hematoxylin and Eosin, original magnification, ×20)  
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Figure 43.   A specimen from group B at 8 weeks filled with enamel matrix derivative  
                   (experimental side), demonstrating areas of hyalinization in plates (Specimens  
                   stained with Hematoxylin and Eosin, original magnification, ×20)  
 
 
 
 
Figure 44.   Saggital histological section through the calvaria showing critical size defect  
            without grafting after 8 weeks. Surgical defect with fibrous connective tissue was  
            thinner than the original calvaria. Interstitial spaces were completely filled with  
            dense connective tissue (Specimens stained with Hematoxylin and Eosin). Arrows 
            indicate the margins of the defect prepared initially.  
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Figure 45.   A specimen from group B at 8 weeks (control side), surgical defect with fibrous  
                    connective tissue was thinner than the original calvaria. Interstitial spaces were  
                    completely filled with dense connective tissue.(Specimens stained with  
                    Hematoxylin and Eosin, original magnification, ×10)  
 
 
 
 
Figure 46.   A specimen from group B at 8 weeks (control side), demonstrating areas of  
                    hyalinization in plates (Specimens stained with Hematoxylin and Eosin, original  
                    magnification, ×20) 
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Histomorphometric analysis 
The histomorphometric analysis demonstrated mean new bone formation that revealed in 
percentage of new bone area (+SD) in Table 2. In group AI, at 2 weeks postsurgery, mean new 
bone formation that revealed in % new bone area ( ± SD ) for bioactive glass with EMD 
(experimental) and bioactive glass alone (control) were 5.34 ± 3.79, 3.64 ± 1.84 respectively. 
In group AII, at 4 weeks postsurgery, mean % new bone area (± SD) for bioactive glass with 
EMD (experimental) and bioactive glass alone (control) were 7.29 ± 3.21, 7.14 ± 7.01 
respectively. 
In group AIII, at 8 weeks postsurgery, mean % new bone area (± SD) for bioactive glass with 
EMD (experimental) and bioactive glass alone (control) were 17.98 ± 7.78, 7.05 ± 2.42 
respectively. And in group B, for only enamel matrix derivative (experimental) and empty 
(control) were 12.12 ± 5.50, 7.78 ± 3.83 respectively. The data was shown that the percentage of 
new bone area in the experimental side was more than the control side in all of group A and 
group B. 
 
Table 2.       The data of histomorphometric analysis (percentage of new bone area)  
                            in group A and B.          
                                                                                                                                                 n = 5 
Group Week Percentage of  new bone area 
(Mean± SD) 
 
AI 
AII 
AIII 
B 
 
 
2 
4 
8 
8 
 
Experiment Control 
           5.34 ± 3.79 
           7.29 ± 3.21 
           17.98 ± 7.78 
           12.12 ± 5.50 
 
           3.64 ± 1.84 
           7.14 ± 7.01 
           7.05 ± 2.42 
           7.78 ± 3.83 
 
Group A    Experimental side = Bioactive glass + Enamel matrix derivative 
                         Control side = Bioactive glass only 
Group B    Experimental side = Enamel matrix derivative only 
                         Control side = Empty 
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Figure 47.   Distribution of percentage of new bone formation from histomorphometry  
                   analysis.  
 
In summery, The data showed that the mean percentage of new bone in the experimental 
side was slightly better than the control side in 2, 4 and 8 weeks in group A and group B. In 
group AIII the difference of new bone between the experimental side and the control side was 
more than the other groups. 
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CHAPTER 4 
 
DISCUSSION 
 
   In the past decade, tissue engineering-based bone grafting has emerged as a viable 
alternative to biological and synthetic grafts. The biomaterial component is a critical determinant 
of the ultimate success of the tissue-engineered graft. Because no single existing material 
possesses all the necessary properties required in an ideal bone graft. Enamel matrix derivative 
(EMD) is a mixture of proteins with amelogenin as a major component that has been 
demonstrated to promote periodontal regeneration. Recently, it has been shown that EMD can 
induce the formation of acellular cementum, collagenous fibers and alveolar bone. However, its 
influence may not be limited to the cementum. Using an in vitro wound model, it has been 
reported that the EMD can enhance wound-filling for all cell exposed to it in culture medium 
when compared to untreated condition.59 EMD have influence bone metabolism through the 
activation of growth factor.60 Takayama et al. reported that EMD promoted the osteogenic 
differentiation of pluripotent mesenchymal cells. This effect was mediated by BMP-like 
molecules present in the EMD.61 Schwartz et al. showed that EMD can affect early stages of 
osteoblastic maturation by stimulating proliferation, but as cells mature in the lineage, EMD also 
enhances differentiation.37 Jiang et al. reported that EMD enhanced gene expression of collagen I 
and IL-6 in primary mouse osteoblasts.62 Moreover, EMD has been reported to sitmulate the 
biosynthesis and regeneration of trabecular bone and the volume fraction of mineralized tissue 
appeared to be higher in EMD- applied bone than in controls.47 EMD has also been found to be 
an effective matrix for enhancing new trabecular bone induction and resulting attachment of 
orthopedic prostheses to the recipient bone.48 In an animal study on dogs, Casati et al. evaluated 
the effect of EMD on bone healing of dehiscence-like osseous defects around dental implants 
with histomorphometry. The authors compared the use of EMD alone, EMD plus bioabsorbable 
barrier membrane, and bioabsorbable barrier membrane alone to a control group in the treatment 
of surgically created dehiscence-like defects around dental implants. The results showed that the 
group treated with EMD plus bioabsorbable barrier membrane had a statistically significant 
higher bone-implant contact percentage than the control group. The authors concluded that EMD 
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might positively influence bone healing around dental implants; however, EMD alone did not 
show any statistically significant effect.52 Same as the result of Cornelini et al, in a study in rabbit 
tibia, there was no difference in bone regeneration between EMD treated and control sites.50 The 
present study was designed to histometrically evaluate the effect of EMD and bioactive glass on 
bone healing of critical-size defects in the calvaria of rats. Bone defect’s size is in agreement with 
previous studies of critical-size defects in various animal models.46 It has to be realized that the 
critical-size defect model represents a challenging situation for bone formation as opposed to 
models using self-contained and/or dehiscence-type defects. The results of the present experiment 
had demonstrated that bioactive glass plus EMD had more new bone area than as was seen in 
bioactive glass alone after healing period 2 , 4 and 8 weeks and the mean optical density found 
the experimental side (bioactive glass plus EMD) had more optical density than control side 
(bioactive glass alone) at 2 and 4 weeks. But at 8 weeks, the mean optical density of experimental 
side and control side is nearly the same. After a healing period of 8 weeks, the percentage of new 
bone in the group of bioactive glass plus EMD is highest, EMD alone, control group and 
bioactive glass alone respectively. The amount of new bone formation comparing between 
bioactive glass alone group and the control group was nearly the same in 8 weeks but when there 
is more resorption of bioactive glass in the later period, the amount of new bone formation might 
be much greater. The slow resorption of the bioactive glass particles probably accounted for the 
greater amount of newly formed bone observed in control group when compared with bioactive 
glass alone group. According to MacNeill et al, graft materials that require extended time periods 
for complete resorption will reduce the total amount of newly formed bone due to their continued 
presence.63 When EMD was apply alone, the magnitude of new bone formation was higher than 
control group. This observation is in the same result as the recent observation in which positive 
influence on bone formation was seen following the application of EMD on calvarial defects of 
rats.49 Bioactive glass has documented osteoconductive and osteostimulatory properties. Hence, 
its use has been recommended in order to provide scaffold for the regeneration of various bone 
defects. In the present model, the narrow granule size range of 300-355 µm leads to an interfacial 
ion exchange throughout the particles, followed by a specific cellular response.19, 21 Like other 
bioactive glass particle of similar composition but different size range, not only do they form a 
Ca-P rich layer on their outer surface, which is responsible for the extensive osteoconductive 
properties, but the particles themselves are eroded internally by phagocytosing cells entering via 
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small cracks.64 Most of the bioactive glass underwent resorption over the time, which reduced 
their diameter and widened the entrance to the internal lumen. When bioactive glass combined 
with EMD 17.98 % of new bone area was observed. This finding show the highest of new bone 
formation at 8 weeks when compare with another group. The observation from the present study 
showed that the group of bioactive glass plus enamel matrix derivative presented more new bone 
formation correspondence with more time period. From this result we can apply to use in tissue 
engineering, the use of ceramic composites as matrices and scaffolds for drug delivery, carrier 
material for enamel matrix derivative. In the study of Cornelini R. et al found the enamel matrix 
derivative alone after implanted in the tibia of rabbit 4 weeks is fully resorbed.50 But in this study, 
there was more bone formation in 8 weeks, this might be the effect of enamel matrix derivative. 
Though bioactive glass was not directly compared with other carrier systems for enamel matrix 
derivative driven bone formation, it would be a promising carrier material with the potential to 
adsorb enamel matrix derivative. 
In this study, bioactive glass could have provided a protected coagulum, preventing the 
decrease in the regeneration space and also helped to keep the EMD in place. The combined 
bioactive glass plus EMD provided more percentage of new bone formation when compared to 
bioactive glass alone, the magnitude of the values indicated some advantage to the combination. 
This result indicate that EMD is an osteopromotive agent.  
From this study, it showed that the association of bioactive glass plus EMD had 
positively influence bone healing since a greater percentage of new bone area was observed when 
compared to the other. The data also indicate that EMD involved with bone healing even in the 
absence of PDL cells. More studies are necessary to evaluate the benefits of EMD associated 
with other regenerative procedures such as bone grafts and guided bone regeneration and also to 
clarify the specific components and mechanisms of action behind the observed effects.   
The finding of the present study should be considered with caution due to the small 
sample size. In addition, direct extrapolation of data obtained from animal studies to humans 
should be interpreted cautiously. 
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CHAPTER 5 
 
CONCLUSION 
 
From the result of this study, we may be concluded that Biograns® with enamel matrix 
derivative made more new bone formation in the rat calvarial bone defects when compare with 
Biograns® alone at 2, 4 and 8 weeks. Enamel metrix derivative alone used in the rat calvarial bone 
defects also made more new bone formation compared with unused defects. Due to the small 
number of rats in this study, to confirm the result, further study needs to be preformed.  
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APPENDIX 
 
Histomorphometric analysis 
The Image-Pro Plus 5.0 program was used for the histomorphometric analysis. The most 
central histological section of each surgical defect was selected for the statistical evaluation. Each 
section was initially inspected using a light microscope ( ×5 objective ) and saved as a digital 
image. A composite digital image was then created by combining 3–4 smaller images because it 
was not possible to capture the entire defect in one image at the level of magnification that was 
used. (Fig. 1) 
 
 
Figure 1. Four capture images of the histological section merged to create a single  
                composite image comprising the entire length of the surgical defect.  
 
 The following criteria were used to standardize the histomorphometric analysis of the 
composite digital image: 1) The captured images of each histological section were merged on the 
computer screen to create a single composite image comprising the entire length of the surgical 
defect. The total area (TA) to be analyzed was then delineated on the composite image. It 
corresponded to the calvarial bone defect where the surgical defect had been previously created.  
              2) The newly formed bone area (NFBA) was also delineated (Fig. 2). The total area (TA) 
was considered 100% of the area to be analyzed (Fig. 3). The percentage of NFBA was 
calculated according to the following formula:  
% new bone    =    new bone area  × 100 
                           Total bone defect area 
The values of percentage of NFBA of each animal were used to calculate the means and 
standard deviations of each control and experimental group. 
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                 Figure 2.  Calculation of the newly formed bone area (NFBA). 
 
 
 
 
 
 
                  
                 Figure 3.  Calculation of the total area (TA). 
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